Main Session
Sep
30
SS 36 - GI 3: Liver - checking in on inhibitors, inSPECTing liver function, and making progress oligo-ly
309 - Efficacy and Safety of Camrelizumab and Apatinib in Combination with IMRT in Unresectable Hepatocellular Carcinoma: A Non-Randomised Phase 2 Study
Presenter(s)
Hong-zhi Wang, MD, MS - Cancer Hospital, Chinese Academy of Medical Science, Peking Union Medical College, BeiJing, Beijing